Table 4.
Differences between iRECIST and iPERCIST classification, observed in 11/28 patients, in relation to survival
| iRECIST | iPERCIST | Nb of patients | Survival in days, mean (± SD)a |
|---|---|---|---|
| SD | PMR | 5 | 520 (± 104) |
| SD | PMD | 2 | 360 (± 234) |
| PD | SMD | 2 | 573 (± 204) |
| PR | CMR | 1 | 967 |
| CR | PMR | 1 | 717 |
iRECIST Immune RECIST, iPERCIST Immune PERCIST, SD Stable disease, PD progressive disease, PR partial response, CR complete response, PMR partial metabolic response, PMD progressive metabolic disease, SMD stable metabolic disease, CMR complete metabolic response
aNB: mean survival for the population study (n = 28) = 479 days (± 248)